MDMA – more commonly known by its party-name ecstasy – is continuing to demonstrate serious potential as a possible form of treatment for post-traumatic stress disorder (PTSD), according to Fortune.
The illicit substance was approved for Phase 3 clinical trials back in November. The drug continues to move closer to Food and Drug Administration approval as a PTSD treatment as the clinical trial produces promising results.
Last month, researchers from this study presented data at the Psychedelic Science 2017 conference in Oakland, California. They reported that the trial, which is in mid-stage, consists of more than 100 PTSD patients and that ecstasy treatment is providing beneficial. According to their findings, when combined with non-medicinal psychotherapy, ecstasy made patients two or three times less likely to experience PTSD symptoms.
Even more significant, the researchers reported that 67 percent of patients treated with MDMA did not exhibit signs of PTSD a year out, whereas only 23 percent of placebo patients reported the same improvement.
The FDA has granted approval for the study to move into the final stage of Phase 3 testings. Once that is completed, the drug will be presented for final approval as a form of PTSD treatment.